ZIM Laboratories
- Market cap
- ₹ 663 Cr.
- P/E
- 158.9x
- P/B
- 2.39x
- 52-week range
- 59.31 – 159.81
- ROE
- 2%
- ROCE
- 5%
- Dividend yield
- 0%
- Debt / equity
- 0.43
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
ZIM Laboratories Limited is a pharmaceutical company. The Company develops, manufactures and supplies oral, solid differentiated generic pharmaceutical formulations and pre-formulation intermediaries (PFI) in various therapeutic segments. Its delivery solutions cover product conceptualization product development, filing for registration, manufacture, and supply of various pharmaceutical formulations. It is developing products in various therapeutic segments like, central nervous system, anti-biotic and anti-infective, gastrointestinal, cardiovascular, analgesic/pain management, urology and vitamins, minerals, and dietary supplements. Its technological capabilities include drug release modification, solubility and stability enhancement, taste masking and dosage form transformation. Its product offerings include finished formulations and pre-formulations intermediates, which include granules, pellets, taste-masked powders, dry suspensions, tablets, capsules, and oral thin films.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →ZIM Laboratories against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)158.9 against a typical 34.3: pricier than most peers (1st = cheapest).204th of 220
- Sales growth+31.2% against a typical +15.6% from a year earlier.54th of 197
- Share price, 3 months+26.3% against a typical −0.5%.26th of 200
- Size₹ 663.1 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).95th of 199
Latest announcements
Exchange filings and their impact on the company.
- 16 Oct 2026Granting/withdrawal/surrender/cancellation/suspension of key licenses/ regulatory approvalsLow impactPositivePrice +3.2% that dayZIM wins Australia TGA GMP certification for Nagpur plant till June 2028, opening Australia and RoW partnership opportunities.
ZIM Laboratories has received GMP compliance certification from Australia's Therapeutic Goods Administration for its Kalmeshwar, Nagpur plant following inspection in April 2026. The certificate, issued on 15 October 2026 and valid until 21 June 2028, covers tablets, capsules, granules, wafers and soluble films. It will help ZIM pursue manufacturing partnerships and product approvals in Australia and support filings in other markets that recognise TGA inspections.
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Moderate safety, with caution
Rated BBB by 2 agencies- CARE expects things to get worse (negative outlook).
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CARE | CARE BBB | Negative | 8 Oct 2026 |
| Acuite | ACUITE BBB | Stable | 17 Feb 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 8 Oct 2026 | ▼ Outlook cut | CARE BBB Outlook Stable → Negative | Medium | CARE | ₹ 139.48 Cr. | |
| 17 Feb 2026 | Reaffirmed | ACUITE BBB | — | Acuite | ₹ 166.23 Cr. | |
| 3 Oct 2025 | Reaffirmed | CARE BBB | — | CARE | ₹ 155.47 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 6 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 19 May 2026 | Financial Results | To consider and approve the financial results for the period ended March 31, 2026 |
| 11 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 21 Jan 2026 | Fund Raising | To consider Fund Raising |
| 12 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 7 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 86 | 96 | 118 | 82 | 92 | 96 | 109 | 72 | 89 | 109 | 105 | 94 |
| Expenses | 77 | 85 | 102 | 74 | 83 | 85 | 94 | 68 | 83 | 96 | 98 | 92 |
| Operating Profit | 9 | 12 | 16 | 8 | 10 | 12 | 15 | 4 | 6 | 13 | 7 | 2 |
| OPM % | 10.9% | 12% | 13.3% | 9.8% | 10.3% | 12% | 13.4% | 5.9% | 6.5% | 11.8% | 6.8% | 2.6% |
| Other Income | 1 | 1 | 2 | 1 | 1 | 2 | 2 | 1 | 2 | 2 | 6 | 1 |
| Interest | 1 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 |
| Depreciation | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Profit before tax | 5 | 7 | 11 | 1 | 3 | 6 | 8 | −2 | −0 | 6 | 5 | −6 |
| Tax % | 23.7% | 31.8% | 26.5% | 27.4% | 19.6% | 30% | 39.7% | −22.6% | 23.5% | 27.3% | 24.3% | −28% |
| Net Profit | 4 | 5 | 8 | 1 | 2 | 4 | 5 | −2 | −0 | 4 | 4 | −4 |
| EPS in Rs | 0.85 | 0.98 | 1.66 | 0.18 | 0.49 | 0.82 | 1 | −0.38 | −0.09 | 0.9 | 0.7 | −0.75 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 3%
- 5 Years
- 4%
- 3 Years
- −2%
- TTM
- 8%
- 10 Years
- −7%
- 5 Years
- −17%
- 3 Years
- −44%
- TTM
- −61%
- 10 Years
- —
- 5 Years
- 22%
- 3 Years
- 2%
- TTM
- —
- 10 Years
- 8%
- 5 Years
- 7%
- 3 Years
- 5%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| ZIM Laboratories | ₹ 143.10 | ₹ 663 Cr. | 158.9x | 2.4x | 2% | — |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
Management
- Anwar Siraj Daud
- Executive Chairman of the Board, Managing Director
- Shyam Mohan Patro
- Chief Financial Officer
- Zulfiquar Kamal
- Director - Finance, Executive Director
- Piyush Siddheshwar Nikhade
- Compliance Officer, Company Secretary
- Niraj Dhadiwal
- Whole - Time Director
- Prakash Sapkal
- Whole - Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.